Longevity
Aging biomarker scientists gather at Harvard to set standards the field still lacks
By John Hyland, . Life and Health Today.
The Biomarkers of Aging Consortium will stage its fourth annual conference on October 5 and 6, 2026, at Harvard Medical School's Joseph B. Martin Conference Center. The two-day meeting is designed to address a problem that sits upstream of almost every longevity therapy in development: nobody has yet agreed on a reliable, standardised way to measure biological aging, and without that, it is very hard to show in a clinical trial whether a treatment is actually doing anything.
A biomarker of aging, in plain terms, is a measurable signal in the body, a pattern in blood chemistry, gene activity, or cell behaviour, that tracks how fast someone is aging biologically rather than just how many years they have lived. The gap between biological age and calendar age is real, but the tools for measuring it are still being debated.
Research into how aging is measured has advanced with remarkable speed, but being fast is not the same thing as being trusted, said Jesse Poganik, Ph.D., who co-chairs the conference, co-directs the Biomarkers of Aging Consortium, and is an investigator at Brigham and Women's Hospital and Harvard Medical School, as quoted by Lifespan.io. "Before an aging biomarker can guide a clinical trial or a treatment decision, the field needs to agree on how it is validated and what it actually tells us."
The program, according to Lifespan.io, will feature close to 30 speakers from universities, research institutes and companies, along with funding agencies and regulatory agencies. Sessions will take in fresh biomarker discovery, methods that pull together several biological data types at once (known as multi-omic methods), analysis built on artificial intelligence, aging of the immune system and of cells, and how biomarkers might serve to evaluate longevity interventions. Poster presenters chosen for it will deliver brief talks, and a jury of experts will hand out prizes.
The conference is co-chaired by Vadim Gladyshev, Chiara Herzog, Andrea Cipriano, Jesse Poganik, and Mahdi Moqri. Chiara Herzog, Ph.D., assistant professor at the University of Cambridge and executive committee member of the Consortium, described the 2026 gathering to Lifespan.io as "our most diverse year yet," spanning molecular screening, population science, and the ethics of longevity, and drawing participants from academia, biotechnology, pharmaceutical companies, and policy.
At Harvard Medical School, the conference sits at the centre of a broader week of programming. A session lasting a full day, devoted to replacement and regenerative approaches in aging, is included within the main event, and tickets also cover a separate Gerophysics Session. On October 7, two satellite symposia will be co-hosted by the Consortium at the same venue: a Brain Aging Symposium in the morning and a Reproductive Aging Symposium in the afternoon.
The Biomarkers of Aging Consortium, according to Lifespan.io, describes itself as a joint effort reaching across more than 50 institutions. Its work includes an open-source platform called Biolearn, a Biomarkers of Aging Challenge, and a study called The Longevity Study. Its fiscal sponsor is the Methuselah Foundation.
What this conference does not do is produce clinical evidence. It is a scientific meeting, not a trial. The open question it is trying to move toward answering is whether the field can converge on validated, standardised biomarkers that regulators will accept as meaningful endpoints in aging trials. Until that happens, a drug or intervention that appears to change a biological age score has not been shown to make anyone live longer or healthier. The meeting's value will be measured by whether it produces that kind of agreement, and that is not something a two-day conference settles on its own.
Source: https://lifespan.io/global-leaders-in-geroscience-convene-for-biomarkers-of-aging/